Edition:
United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,620JPY
7:00am BST
Change (% chg)

¥-34 (-2.03%)
Prev Close
¥1,653
Open
¥1,644
Day's High
¥1,647
Day's Low
¥1,616
Volume
8,095,500
Avg. Vol
8,083,967
52-wk High
¥1,837
52-wk Low
¥1,358

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.59
Market Cap(Mil.): ¥3,560,270.00
Shares Outstanding(Mil.): 2,153.82
Dividend: 17.00
Yield (%): 1.94

Financials

  4503.T Industry Sector
P/E (TTM): 16.45 37.62 37.34
EPS (TTM): 100.51 -- --
ROI: 16.06 14.78 14.24
ROE: 17.09 15.65 15.22

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc , beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. | Video

22 Aug 2016

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc , beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion (11 billion pounds) in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. | Video

22 Aug 2016

UPDATE 5-Pfizer boosts cancer drug roster with $14 bln Medivation deal

Aug 22 Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.

22 Aug 2016

BRIEF-Astellas Pharma submits new drug application for extended-release tablets of quetiapine fumarate in Japan

* Says it submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder

09 Aug 2016

BRIEF-Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration

* Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration

08 Aug 2016

BRIEF-Astellas Pharma unit to sell Astellas Pharma Technologies to Avara

* Says its unit to sell Astellas Pharma Technologies, Inc. to Avara Norman Pharmaceutical Services, Inc (Avara) on Aug. 4 (U.S time)

04 Aug 2016

BRIEF-Astellas to transfer U.S. manufacturing unit to Avara

* Astellas announces transfer of U.S. manufacturing subsidiary to Avara

04 Aug 2016

BRIEF-Cytokinetics Inc reports q2 2016 financial results

* Will not update financial guidance until Q3 earnings due to recent expansion of collaboration with Astellas

28 Jul 2016

BRIEF-Cytokinetics, Astellas announce option right for Tirasemtiv

* Cytokinetics and Astellas announce option right for Tirasemtiv and expansion of global collaboration for CK-2127107 in ALS

27 Jul 2016

BRIEF-Xcelra enters into drug collaboration with Astellas Pharma

* Xcelra enters into a drug repurposing collaboration with Astellas Pharma

07 Jun 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
£10.00
Provider : GlobalData
£195.00
Provider : MarketLine
£33.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.